Sagimet Biosciences (SGMT) investor relations material

Introduction and agenda

• Virtual KOL event reviewed 52-week Phase 3 open-label extension data for denifanstat in moderate to severe acne and plans for the U.S. AURORA Phase 3 trial.

• Agenda covered company overview, clinical perspective and data, development programs, and Q&A; speakers included Dave Happel, Julie Harper, MD, and Andreas Grauer, MD.

KOL background and credentials

• Julie Harper is a board-certified dermatologist, Founding Director and past President of the American Acne and Rosacea Society, and an AAD Fellow.

Market insights and analysis

• Acne affects 50 million people in the U.S. annually; ~10 million have moderate-to-severe acne, and more than 5 million seek medical treatment each year.

• Acne affects ~85% of people aged 12–24; moderate-to-severe disease represents ~20% of U.S. acne sufferers, and chronic management is common.

• Global acne market projected to reach $20 billion by 2034, with unmet need tied to limitations of current therapies, including antibiotic resistance concerns and isotretinoin restrictions.

• FASN inhibition targets sebum lipid production and inflammation; denifanstat reduced cutaneous sebum DNL lipids in Phase 1 trials.